Krsnaa Diagnostics Limited has published the notice for its postal ballot process in newspapers on June 04, 2026, to seek shareholder approval for the re-appointment of an existing director and the appointment of two new independent directors. The resolutions also include approval for the payment of remuneration by way of commission to independent directors. The e-voting period is scheduled from June 05, 2026, to July 04, 2026, providing shareholders a window to vote on these key governance matters.

The company proposes the re-appointment of Mr. Chetan Desai as a Non-Executive Independent Director for a second term of five years, commencing from April 25, 2026. Additionally, the notice seeks approval for the appointment of Mr. Raju Venkatraman and Ms. Lilian Jessie Paul as Non-Executive Independent Directors for a term of two years, also starting from April 25, 2026. All three appointments are subject to the approval of shareholders and regulatory compliance.

Postal Ballot Schedule

The company has established the following timeline for the e-voting process. Shareholders holding shares as of the cut-off date are eligible to participate.

Resolutions Put to Vote

Shareholders will vote on four special resolutions. The first concerns the re-appointment of Mr. Chetan Desai, while the second and third relate to the appointment of Mr. Raju Venkatraman and Ms. Lilian Jessie Paul, respectively. The fourth resolution seeks approval for the payment of remuneration by way of commission to the Independent Directors of the company, within the limits prescribed under the Companies Act, 2013, and SEBI Listing Regulations.

Director Profiles

Mr. Chetan Desai, aged 75, is a Chartered Accountant with approximately 50 years of experience in corporate governance and auditing. He received remuneration amounting to ₹11,00,000 during FY 2025-26. Mr. Raju Venkatraman, aged 67, is a graduate from IIT Madras and a serial entrepreneur with expertise in the diagnostics and healthcare sectors. Ms. Lilian Jessie Paul, aged 56, holds an MBA from IIM Calcutta and brings over 25 years of experience in marketing strategy and corporate strategy.

The results of the e-voting will be announced within two working days from the conclusion of the postal ballot e-voting period. The notice is available on the company's website and the NSDL e-voting portal.

Krsnaa Diagnostics Limited reported a profit after tax (PAT) of ₹1,014 million for the financial year ended March 31, 2026, marking a 31% increase from the previous year. Revenue from operations for FY26 stood at ₹7,728 million, while EBITDA grew to ₹2,149 million with margins of 27.81%. The Board of Directors has recommended a dividend of ₹2 per share, representing 40% of the face value. The disclosures were made pursuant to Regulation 30 read with Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Financial Performance

The company achieved its highest-ever quarterly collection in Q4 FY26 at ₹1,580 million, contributing to total half-year collections of ₹2,910 million. Days sales outstanding (DSO) improved to 139 days by the end of Q4, down from 155 days in the previous quarter. The retail business segment grew sixfold, scaling from ₹10 crores in FY25 to ₹60 crores in FY26, now contributing approximately 8% to total revenue.

Operational Expansion

Krsnaa Diagnostics operates 190-plus CT and MRI centers and 147 pathology laboratories, supported by over 4,700 patient collection centers across 18 states. The company processed nearly 59 million tests and served approximately 20 million patients during the year. Management highlighted a long-term revenue visibility of ₹6,000 crores to ₹7,000 crores over the next 5 to 7 years from existing operations and newly secured business.

Strategic Outlook

The company has planned a capital investment of ₹5,000 million for FY27, covering commitments from Rajasthan projects, radiology expansions, and retail infrastructure. The Rajasthan project is expected to contribute revenues starting Q1 FY27, with a full-year potential estimated between ₹100 crores and ₹150 crores. Management aims to reduce DSO to sub-120 days in FY27 and maintain EBITDA margins at current levels despite ramp-up costs.

Source: https://lodr-files.dhan.co/lodr-inputs/Company/INE08LI01020/f94e67b89e874b34.pdf